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Abstract: The present study employs time of flight mass spectrometry for quantitative analysis of the local anesthetic drugs ropivacaine 
and bupivacaine in authentic, pharmaceutical and spiked human plasma as well as in the presence of their impurities 2,6-dimethylaniline 
and alkaline degradation product. The method is based on time of flight electron spray ionization mass spectrometry technique without 
preliminary chromatographic separation and makes use of bupivacaine as internal standard for ropivacaine, which is used as internal 
standard for bupivacaine. A linear relationship between drug concentrations and the peak intensity ratio of ions of the analyzed substances 
is established. The method is linear from 23.8 to 2380.0 ng mL-1 for both drugs. The correlation coefficient was 0.996 in authentic 
and spiked human plasma. The average percentage recoveries in the ranges of 95.39%–102.75% was obtained. The method is accurate 
(% RE  5%) and reproducible with intra- and inter-assay precision (RSD%  8.0%). The quantification limit is 23.8 ng mL-1 for both 
drugs. The method is not only highly sensitive and selective, but also simple and effective for determination or identification of both 
drugs in authentic and biological fluids. The method can be applied in purity testing, quality control and stability monitoring for the 
studied drugs.
Keywords: ropivacaine, bupivacaine, 2,6-dimethylaniline, time of flight mass spectrometry, pharmaceutical formulations, spiked 
plasmasalama and Wang
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Introduction
Mass spectrometry (MS) is one of the most powerful 
analytical techniques, particularly for pharmaceutical 
analysis, where good selectivity and high sensitivity 
are  often  needed.  In  the  pharmaceutical  industry 
measurements  of  drugs  and  their  metabolites 
in  plasma  are  essential  for  drug  discovery  and 
development.  The  more  accurate  and  rapid  these 
measurements, the more quickly a drug can progress 
towards  regulatory  approval.  Time-of-flight  mass 
spectrometer  (TOF-MS)  delivers  high  sensitivity, 
resolution, and exact mass measurements. A variety of 
ion source and software options makes MS a versatile 
choice for a range of analytical challenges.1–5
Bupivacaine (Bup), a member of the pipecoloxylidide 
group  (Fig.  1),  is  the  most  commonly  used  local 
anesthetic. Commercial Bup is the optically inactive 
racemic (RS) mixture of R- and S-Bup. Several recent 
studies have demonstrated that systemic exposure to 
excessive quantities of Bup result in cardio toxicity 
due to its high affinity for, and dwell time at, voltage-
gated  sodium  channels. A  promising  alternative  to 
Bup is ropivacaine. Ropivacaine (Rop) is a structural 
derivative of Bup that differs only by the replacement 
of the butyl group on the piperidine nitrogen atom of 
Bup with a propyl group (Fig. 1). The minor structural 
modification leads to a reduced hydrophobicity and 
the  decreased  ability  to  diffuse  into  the  heart  and 
brain. As a result, Rop has lower systemic toxicity 
than  Bup.  In  addition,  Rop  is  manufactured  as  a 
pure S-enantiomer, further lowering the cardiotoxic 
potential. Both drugs act by blocking the conduction of 
impulses in target nerve structures, primarily located 
within  the  subarachinoid  space.6–8  Several  methods 
using GC with9,10 or without MS,11 high performance 
liquid  chromatography  (HPLC)  with  UV,12–14  mass 
spectrometery (MS)15–17 or amperometric detection,18 
and capillary electrophoresis19 have been developed to 
analyze the drugs and their impurities in pharmaceutical 
formulations and/or biological fluids.
The aim of this study is to develop rapid, accurate 
and simple method for determination of both drugs 
in authentic, pharmaceutical, spiked human plasma 
as  well  as  in  presence  of  their  impurities  without 
chromatographic separation. The described method 
was not investigated previously.
In this work we describe how a simple TOF ES-MS 
analytical method can be used to determine Bup and 
Rop in authentic and pharmaceutical formulations as 
well as in spiked human plasma. The technique has 
many advantages; no need for method development, 
a  short  analytical  time  (1.5  min),  and  a  minimal 
amount of solvent being required, coupled with high 
sensitivity, selectivity and exact mass measurements.
experimental
Materials and reagents
Ropivacaine  was  kindly  supplied  by  AstraZeneca 
Co.,  UK,  certified  to  contain  99.00%,  CAS  No. 
132112-35-7. NaropinTM vial containing 7.5 mg mL-1 
ropivacaine hydrochloride (AstraZeneca Co., UK) was 
purchased from local market. Bupivacaine was kindly 
supplied by Al-Debeiky Pharma Co., Egypt, its purity 
was  found  to  be  99.60%  according  to  BP  2008. 
Bucain  vial  containing  5.0 mg  mL-1  bupivacaine 
hydrochloride  (DeltaSelect,  GmbH,  Germany)  was 
purchased from the market. Human plasma was kindly 
donated from volunteers. The following reagents and 
1+&2 1 1+&2 1
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Figure 1. Chemical structures of ropivacaine, bupivacaine and their impurity 2,6-dimethylaniline.Quantitative mass spectrometric analysis of ropivacaine
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solvents  were  purchased  and  used  without  further 
purification: 2,6-dimethylaniline (99.00% Aldich UK, 
CAS  No.  87-62-7),  methanol,  chloroform  (HPLC 
grade,  Fisher  Scientific,  UK),  acetonitrile  (LC-MS 
grade, Reidel-dehaen, UK), ultra pure water (ELGA, 
UK),  formic  acid  (Sigma-Aldrich,  UK),  sodium 
hydroxide (BDH, UK) and hydrochloric acid (Certified 
Fisher Scientific, UK).
TLC-separation
Pre-coated TLC plates (10 × 10 cm, aluminium plates 
coated with 0.25 mm silica gel F254) were purchased 
from  Merck  UK.  UV-Radiation  (Cole-Parmer 
Instrument, France) detective wavelength was 254 nm.
TOF-es Ms measurements
The  TOF-ES-MS  measurements  were  performed 
using  WATERS—2795  (Waters,  UK)  equipped 
with  an  autosampler  injector  (10 µL)  and  Mass 
Lynx v 4.1. The system was operating in the following 
regime: electrospray voltage, 3  kv; capillary temperature, 
150 °C; sample solution flow rate, 0.1 mL/min. All 
analysis was performed in the positive ion detection 
mode. All samples were dissolved in a 50% solution of 
acetonitrile in water containing 0.1% formic acid.
Preparation of alkaline degradation 
products
The degradation products were laboratory prepared 
by  heating  10 mg  of  bupivacaine  hydrochloride 
in 1 M NaOH (10 mL) for 4 hours on hot plate at 
temperature 100 °C. The solution was neutralized with 
1M HCl then the solution was evaporated and diluted 
to 10 mL with methanol. Complete degradation was 
monitored by TLC. The TLC separation was carried 
out by using chloroform-methanol (9:1 v/v) as the 
mobile phase.20 The Rf value is 0.71% ± 0.002% for 
both drugs. The major alkaline degradation product, 
namely 2,6-dimethylaniline, which has an Rf value of 
0.81% ± 0.001% as identified by comparison with the 
reference standard.
standard solutions and calibration 
curves
Stock solutions of ropivacaine and bupivacaine were 
prepared in methanol at a concentration of 1 mg mL -1, 
and stored at 4 °C. These were further diluted with 
50% aqueous acetonitrile containing 0.1% formic acid 
to give the appropriate working solutions. Working 
solutions of each drug were prepared to yield final 
concentrations  of  23.8,  59.5,  119.0,  238.0,  595.0, 
1190.0 and 2380.0 ng mL -1 by further dilution with the 
same solvent. Bupivacaine (2380.0 ng mL-1) was used 
as IS for ropivacaine. Ropivacaine (2380.0 ng mL-1), 
was used as IS for bupivacaine.
Preparation of spiked human plasma
Aliquots equivalent to 71.4 – 7140.0 ng mL-1 of each 
drug and 7140.0 ng mL-1 of the internal standard in 
1 mL plasma were sonicated for 5 minutes. Acetonitrile 
(2 mL) was added and then centrifuged at 7000 rpm 
for 30 minutes. One milliliter of the supernatant was 
evaporated.
Laboratory prepared solutions
Mixtures of ropivacaine and bupivacaine were prepared 
by  mixing  different  concentrations  of  each  drug 
with  its  impurity  (2,6-dimethylaniline)  and  alkaline 
degradation product, where the ratio 0.1%–10.0% of 
the mixtures were obtained.
Procedure
Ten µL each of the above solutions was injected in 
the TOF-ES-MS under conditions mentioned above. 
The  characteristic  m/z  ions  used  for  identification 
and determination of Rop, Bup and 2,6-DMA were 
m/z  =  275,  m/z  =  289  and  m/z  =  122  [M  +  H]+, 
respectively.
Analysis of pharmaceutical preparations
Milliliters equivalent to 50 mg from the corresponding 
drug vial were transferred quantitatively into 50 mL 
volumetric flasks and made up to the volume with 
methanol. The procedure was completed as mentioned 
above.
Calculations
The  calibration  curves  were  calculated  by 
unweighted  least-squares  linear  regression  analysis 
of the concentrations of the analyte versus the peak 
intensity  ratio  of  ions  of  analyzed  substance  of 
ropivacaine (m/z 275) to that of the IS (m/z 289). 
As for bupivacaine (m/z 289) to that of IS (m/z 275) 
was used. Concentrations of unknown samples were 
determined by applying the linear regression equation salama and Wang
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of the standard curve to the unknown sample’s peak 
intensity ratio.
Method Validation
Limit of quantification
The limit of quantification of the two drugs was defined 
as the lowest concentration of the calibration curve.
Precision and accuracy
Precision  and  accuracy  were  assessed  by  assaying 
freshly  prepared  solutions  of  the  two  drugs  in 
triplicate at three concentration levels; 59.5, 1190.0 
and 2380.0 ng mL-1. Precision is reported as relative 
standard  deviation  (RSD%)  of  the  estimated 
concentrations  and  accuracy  (%  Relative  error) 
expressed as [measured-nominal/nominal × 100].
Selectivity and specificity
Specificity is the ability of the method to measure the 
analyte response in the presence of impurity and or 
degradation products. For specificity determination, 
synthetic  mixtures  of  different  percentages  of 
2,6-dimethylaniline  and  degradation  products  of 
each drug were added to each pure drug sample. The 
recovery percent was calculated.
Results and Discussion
The work includes (1) mass spectrometric identification 
and determinations of ropivacaine and bupivacaine; 
(2) generation of the standard calibration curves; (3) 
identification and determination of drug substances 
in spiked human plasma; (4) determination of both 
drugs  in  presence  of  alkaline  degradation  and/or 
impurity(2,6-DMA);  and  (5)  quantitative  analysis 
of  the  individual  ropivacaine,  bupivacaine  in  their 
pharmaceutical preparations.
The mass spectra of ropivacaine and bupivacaine 
and  their  internal  standards  are  shown  in  Figure  2. 
Under the conditions of TOF ES-MS in positive mode, 
the spectra displays intense peaks of [M + H]+ with ions 
of the highest mass to charge, e.g. m/z = 275.2154 for 
ropivacaine and 289.2226 for bupivacaine, respectively. 
Linearity  range  was  found  to  hold  good  over  a 
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Figure 2. The typical Mass spectra of (A) ropivacaine, 2380.0 ng mL-1 (B) bupivacaine, 2380.0 ng mL-1 (c) ropivacaine (1190.0 ng mL-1, analyte) and 
bupivacaine (2380.0 ng mL-1, internal standard) in 50% aqueous solution of acetonitrile containing 0.1% formic acid.Quantitative mass spectrometric analysis of ropivacaine
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concentration range of 23.8 – 2380.0 ng mL-1 for both 
drugs. The results of regression data are presented in 
Table 1.
Analysis  of  studied  drugs  in  spiked  human 
plasma are shown in Figure 3. The linearity was in 
the range of 59.5–2380.0 ng mL-1 for Rop while it is 
within 23.8–2380.0 ng mL-1 for Bup in 1 mL plasma 
sample, which is the anticipated concentration range 
in  clinical  investigation  of  drug  pharmacokinetics. 
The maximum plasma level of Rop and Bup after 
different  rout  of  administrations  were  found  to  be 
more than 100 ng mL-1 21–23 which could be assessed 
by the proposed method. The high sensitivity of the 
proposed method allowed the determination of both 
drugs  in  spiked  human  plasma.  Linear  regression 
analysis of the data gives the equations, A = 0.02707 
C  +  0.0082,  r  =  0.996,  for  Rop  and  A  =  0.5441 
C – 0.0137, r = 0.999, for Bup. Where A is the peak 
intensity ratio for m/z = 275/289 for Rop and 289/275 
for Bup, C is the concentration in ng mL-1 and r is 
correlation coefficient.
The data stated in Table 1, indicate that the method 
is efficient for determination of the studied drugs in 
biological fluids as there is no significant differences 
between the results for determinations of both drugs 
in authentic and spiked plasma samples.
Validation Data
Linearity and limit of quantification
Calibration curves for ropivacaine and bupivacaine 
exhibited  good  linearity  over  the  concentration 
range studied (23.8–2380.0 ng mL-1) for both drugs 
in authentic and spiked human plasma as stated in 
Table 1. From the results, it is clear that there is no 
interference from the plasma matrix demonstrating the 
efficiency for determination of the drugs in biological 
fluids  by TOF  ES-MS. The  limit  of  quantification 
(LOQ) was chosen as the lowest calibration standard 
concentration (23.8 ng mL-1) for the studied drugs in 
authentic and spiked human plasma.
Precision and accuracy
Table 2 summarizes mean values, precision, and accuracy 
of intra- and inter-assay analysis. Precision and accuracy 
were within the ranges acceptable for analytical and 
bio-analytical  purposes.  Intra-day  precision  ranged 
from  0.60  to  3.61%  for  ropivacaine  while  2.16  to 
3.33% for bupivacaine in drug substances. While in 
spiked human plasma ranged from 1.07 to 7.98% for 
ropivacaine  and  from  0.95  to  5.13  for  bupivacaine 
(Table 3). Inter-day precision did not exceed 8.0% over 
the three level concentrations for three days in drug 
substances and spiked human plasma. The accuracy 
Table 1. Linearity, recovery and LOQ of TOF es-Ms assay for ropivacaine and bupivacaine in authentic and spiked human 
plasma.
parameters Ropivacaine Bupivacaine
Authentic spiked human   
plasma
Authentic spiked human 
plasma
Linearity ng mL-1 23.8–2380.0 59.5–2380.0 23.8–2380.0 23.8–2380.0
regression equation
slope (b)a 0.3645 0.02707 0.6227 0.5441
se of slope 0.007813 0.011644 0.016894 0.013801
Intercept (a)a 0.0133 0.0082 0.0266 -0.0137
se of intercept 0.009564 0.01303 0.018896 0.016894
Correlation
coefficient (r) 0.999 0.996 0.998 0.999
se of estimation 0.014768 0.023327 0.034049 0.026085
recovery
Meanb ± rsD% 98.83 ± 3.03 95.39 ± 3.64 99.61 ± 3.20 99.96 ± 2.88
LOQ ng mL-1 23.8 59.9 23.8 23.8
aregression equation, A = a + bc, where A is the peak intensity ratio for m/z = 275.0 /289.0 for rop, and A is the peak intensity ratio for m/z = 289.0/275.0 
for Bup, C is the concentration.
bn = 6.salama and Wang
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Table 2. Intra and inter-day precision and accuracy of TOF es-Ms assay for ropivacaine and bupivacaine in authentic 
samples.
Drug 
substances
conc. ng mL-1 precisiona RsD% Accuracya Re%
Inter Intra Inter Intra
ropivacaine 59.5
1190.0
2380.0
3.61
1.72
0.60
3.57
2.02
1.18
-4.67
-0.58
-2.34
4.59
-2.19
2.00
Bupivacaine 59.5
1190.0
2380.0
3.33
2.16
2.61
5.16
2.01
0.96
2.86
1.05
1.50
3.12
2.30
3.12
an = 3.
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100.00
100.00
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Figure 3. The mass spectra of spiked human plasma (A) human plasma, control (B) bupivacaine, 1190.0 ng mL-1 (c) ropivacaine, 1190.0 ng mL-1, 
(D) mixture of bupivacaine, 23.8 ng mL-1 (analyte) and ropivacaine, 2380.0  ng mL-1 (Is) in 50% aqueous solution of acetonitrile containing 0.1% formic 
acid. Quantitative mass spectrometric analysis of ropivacaine
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Table 3. Intra and inter-day precision and accuracy of TOF es-Ms assay for ropivacaine and bupivacaine in spiked human 
plasma.
Drug 
substances
conc. ng mL-1 precisiona RsD% Accuracya Re%
Intra Inter Intra Inter
ropivacaine 59.5
1190.0
2380.0
7.98
3.88
1.07
6.50
5.75
1.40
-3.67
1.90
0.85
-2.00
3.04
2.50
Bupivacaine 59.5
1190.0
2380.0
5.13
1.95
0.95
4.85
2.74
2.99
3.66
-1.07
0.33
-1.62
0.22
0.10
an = 3.
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Figure 4. The mass spectra of (A) 2,6-dimethylaniline (B) Alkaline degradation products (c) mixture of ropivacaine, 2380.0 ng mL-1 (internal standard), 
bupivacaine 1190.0 ng mL-1 (analyte) and their impurity 2,6-dimethylaniline (D) mixture of both drugs with alkaline degradation products, in 50% aqueous 
solution of acetonitrile containing 0.1% formic acid.salama and Wang
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Table 4. Specificity of TOF ES-MS assay for ropivacaine 
and bupivacaine in authentic samples.
Degradation products 
and/or 2,6-DMA%
Recoverya % ± RsD%
Ropivacaine Bupivacaine
0.1 99.79 ± 2.47 100.04 ± 2.77
1.0 101.05 ± 2.16 100.02 ± 1.04
10.0 98.48 ± 1.29 98.18 ± 1.67
aMean of four different experiments.
Table 5. results for the determination of ropivacaine and 
bupivacaine in pharmaceutical formulations by the proposed 
TOF es-Ms method.
preparations TOF es-Ms
Mean recoverya % RsD%
naropin vial, 7.5 mg mL-1 
ropivacaine hydrochloride
102.75 1.75
Bucain vial, 5.0 mg mL-1 
bupivacaine hydrochloride
100.33 2.51
aMean of five experiments.
of  the  technique  was  considered  satisfactory,  since 
between-day  variation  over  the  concentration  range 
studied was found to be less than 5%.
Selectivity and specificity
Ropivacaine and bupivacaine are amides expected to 
alkaline degradation through cleavage of amide linkage 
with production of 2,6-dimethylaniline. Solutions of 
alkaline  degradations  of  each  were  tested  by  TLC 
against pure sample of 2,6-dimethylaniline. The same 
spots of each have the same Rf (0.81) of the pure 
compound.  For  further  confirmation,  TOF-ES-MS 
was carried for each of both compounds. The product 
obtained from alkaline degradation has m/z = 122.1935 
corresponds to protonated 2,6-dimethylaniline.
The  mass  spectrometric  determinations  of  Rop 
and Bup in the presence of their alkaline degradation 
products are shown in Figure 4. Synthetic compound 
2,6-dimethylaniline  was  used  as  control,  and  in  the 
spectrum (A) the ion of the mass to charge (m/z) 122.1935 
corresponding to 2,6-dimethylaniline was identified. The 
highest ion peak was m/z = 163.1910 (122 + 41) which 
might be resulted in acetonitrile solvent interference in 
the system. The same peaks appeared in the spectrum 
(B) and 2,6-dimethylaniline was the major degradation 
product of bupivacaine. In addition, a relative low of 
molecular ion peak at m/z = 102.2419 was observed 
which may be assigned as a m-xylene ion. The spectra 
(C)  and  (D)  display  the  intensive  ion  peaks  with 
m/z = 122.1935 [M + H]+ for 2,6-dimethylaniline clearly 
indicating 2,6-dimethylaniline to be the major alkaline 
degradation product of Rop and Bup. The specificity 
was  also  assessed  by  analyzing  synthetic  mixtures 
of each drug with its alkaline degradation product in 
concentration ranging from 0.1 to 10.0%. The results 
reveal the high selectivity and sensitivity of the method 
which can determine the impurity in concentration down 
to 0.1% present in both drugs (Table 4).
Analysis of pharmaceutical preparations
The method was applied to determine ropivacaine and 
bupivacaine in Naropin and Bucaine vial respectively. 
The % RSD was less than 3.0%, indicating the precision 
of the method, the results are presented in Table 5.
conclusion
In this manuscript, we described a newly developed 
TOF-MS based method for quantitative determination of 
ropivacaine and bupivacaine in authentic, pharmaceutical 
dosage forms and the spiked human plasma without 
chromatographic  separation.  The  strategy  of  this 
approach consists in direct multi-ion detection of analytes 
with reference to internal standards with close structures 
to the analyte. The method can also be used to identify 
the degradation products in minute amounts in presence 
of the corresponding ropivacaine or bupivacaine. The 
method could be routinely used for quantitative drug 
analysis in pharmaceutical formulations and biological 
media as well as for assessing drug purity and stability.
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